Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA

Molecular Pharmacology

Volumn 50, Issue 5, 1996, Pages 1095-1102

  Nitiss, John L ^a   Wang, James C ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FUNGAL DNA; GYRASE INHIBITOR; NOCODAZOLE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL KILLING; CONTROLLED STUDY; DRUG DNA BINDING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE;

AMSACRINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DEATH; DNA; DNA DAMAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; G1 PHASE; PEPTIDES; S PHASE; SACCHAROMYCES CEREVISIAE;

EID: 0029847080     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Froelich-Ammon, S. J., and N. Osheroff. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270:21429-21432 (1995).
2. Beck, W. T., M. K. Danks, J. S. Wolverton, R. Kim, and M. Chen. Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul. 33:113-127 (1993).
3. Chen, A. Y., and L. F. Liu. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:191-218 (1994).
4. Drlica, K., and R. J. Franco. Inhibitors of DNA topoisomerases. Biochemistry 27:2253-2259 (1988).
5. Wang, J. C. DNA topoisomerases as targets of therapeutics: an overview. Adv. Pharmacol 29:1-19 (1994).
6. Kjeldsen, E., J. Q. Svejstrup, I.I. Gromova, J. Alsner, and O. Westergaard. Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol. 228:1025-1030 (1992).
7. Robinson, M. J., and N. Osheroff. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzymemediated DNA religation by 4′-(9-acridinylamino)methanesulfon-manisidide. Biochemistry 29:2511-2515 (1990).
8. Yamashita, Y., Y. Saitoh, K. Ando, K. Takahashi, H. Ohno, and H. Nakano. Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces [Letter). J. Antibiot. (Tokyo) 43:1344-1346 (1990).
9. Reece, R. J., and A. Maxwell. DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol. 26:335-375 (1991).
10. Ishida, R., M. Hamatake, R. A. Wasserman, J. L. Nitiss, J. C. Wang, and T. Andoh. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res. 55:2299-2303 (1995).
11. Drake, F. H., G. A. Hofmann, S. M. Mong, J. O. Bartus, R. P. Hertzberg, R. K. Johnson, M. R. Mattern, and C. K. Mirabelli. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 49:2578-2583 (1989).
12. Nitiss, J. L. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv. Pharmacol. 29:103-134 (1994).
13. Cotten, M., D. Bresnahan, S. Thompson, L. Sealy, and R. Chalkley. Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase. Nucleic Acids Res. 14:3671-3686 (1986).
14. Snapka, R. M. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. Mol. Cell. Biol. 6:4221-4227 (1986).
15. D'Arpa, P., C. Beardmore, and L. F. Liu. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 60:6919-6924 (1990).
16. Avemann, K., R. Knippers, T. Koller, and J. M. Sogo. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell. Biol. 8:3026-3034 (1988).
17. Hsiang, Y. H., M. G. Lihou, and L. F. Liu. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082 (1989).
18. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375 (1989).
19. Perez, C., F. Pelayo, N. E. Vilaboa, and P. Aller. Caffeine attenuates the action of amsacrine and etoposide in U-937 cells by mechanisms which involve inhibition of RNA synthesis. Int. J. Cancer 57:889-893 (1994).
20. Pommier, Y., D. Kerrigan, J. M. Covey, C. S. Kao-Shan, and J. Whang-Peng. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res. 48:512-516 (1988).
21. Pommier, Y., F. Leteurtre, M. R. Fesen, A. Fujimori, R. Bertrand, E. Solary, G. Kohlhagen, and K. W. Kohn. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542 (1994).
22. Nitiss, J., and J. C. Wang. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA 85:7501-7505 (1988).
23. Nitiss, J. L., Y. X. Liu, P. Harbury, M. Jannatipour, R. Wasserman, and J. C. Wang. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 52:4467-4472 (1992).
24. Worland, S. T., and J. C. Wang. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264:4412-4416 (1989).
25. Marini, J. C., K. G. Miller, and P. T. England. Decatenation of kinetoplast DNA by topoisomerases. J. Biol. Chem. 255:4976-4979 (1980).
26. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).
27. Eng, W. K., L. Faucette, R. K. Johnson, and R. Sternglanz. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:755-760 (1988).
28. Goto, T., and J. C. Wang. Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II. Proc. Natl. Acad. Sci. USA 82: 7178-7182 (1985).
29. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 61:1129-1136 (1991).
30. Cortes, F., and J. Pinero. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother. Pharmacol. 34:411-415 (1994).
31. Nitiss, J. L., and J. C. Wang. Yeast as a genetic system in the dissection of the mechanism of cell killing by topoisomerase-targeting anti-cancer drugs, in DNA Tapoisomerases and Cancer (M. Potmesil and K. Kohn, eds.). Oxford University Press, London, 77-91 (1991).
32. Schmidt, V. K., B. S. Sorensen, H. V. Sorensen, J. Alsner, and O. Westergaard. Intramolecular and intermolecular DNA ligation mediated by topoisomerase II. J. Mol. Biol. 241:18-25 (1994).
33. Kessel, D., and R. Dysard. Effects of camptothecin on RNA synthesis in L-1210 cells. Biochim. Biophys. Acta 312:716-721 (1973).
34. Howard, M. T., S. H. Neece, S. W. Matson, and K. N. Kreuzer. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc. Natl. Acad. Sci. USA 91:12031-12035 (1994).
35. Berger, N. A., S. Chatterjee, J. A. Schmotzer, and S. R. Helms. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc. Natl. Acad. Sci. USA 88:8740-8743 (1991).
36. Sullivan, D. M., B. S. Glisson, P. K. Hodges, S. Smallwood-Kentro, and W. E. Ross. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 26:2248-2256 (1986).
37. Liu, Y. X., Y. Hsiung, M. Jannatipour, Y. Yeh, and J. L. Nitiss. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res. 54:2943-2951 (1994).
38. Nitiss, J. L., Y. X. Liu, and Y. Hsiung. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res. 53:89-93 (1993).
39. Uemura, T., and M. Yanagida. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J. 3:1737-1744 (1984).